Rafael Maldonado Selected Research

N- piperidinyl- (8- chloro- 1- (2,4- dichlorophenyl)- 1,4,5,6- tetrahydrobenzo(6,7)cyclohepta(1,2- c)pyrazole- 3- carboxamide)

8/2016

Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rafael Maldonado Research Topics

Disease

26	Pain (Aches) 03/2022 - 02/2003
19	Substance-Related Disorders (Drug Abuse) 03/2022 - 06/2004
14	Neuralgia (Stump Neuralgia) 01/2021 - 01/2006
11	Hyperalgesia 01/2021 - 02/2004
9	Obesity 01/2022 - 03/2010
8	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 01/2012
8	Hypersensitivity (Allergy) 01/2021 - 05/2002
8	Tobacco Use Disorder (Nicotine Dependence) 08/2012 - 02/2005
7	Cognitive Dysfunction 02/2021 - 01/2012
5	COVID-19 04/2022 - 01/2020
5	Chronic Pain 03/2022 - 06/2011
5	Cocaine-Related Disorders (Cocaine Addiction) 10/2021 - 06/2004
5	Osteoarthritis 10/2019 - 02/2014
5	Tremor (Tremors) 11/2013 - 03/2004
4	Opioid-Related Disorders (Opiate Addiction) 08/2021 - 06/2004
4	Body Weight (Weight, Body) 01/2020 - 03/2010
3	Anxiety Disorders (Anxiety Disorder) 05/2022 - 02/2015
3	Postoperative Pain 01/2021 - 03/2006
3	Endometriosis 01/2021 - 01/2020
3	Fragile X Syndrome (Martin Bell Syndrome) 01/2021 - 05/2013
3	Intellectual Disability (Idiocy) 03/2020 - 05/2013
3	Neurobehavioral Manifestations 01/2020 - 10/2015
3	Neuroinflammatory Diseases 10/2019 - 01/2013
3	Mental Disorders (Mental Disorder) 01/2019 - 11/2011
3	Parkinson Disease (Parkinson's Disease) 04/2017 - 03/2014
3	Catalepsy 01/2017 - 08/2006
3	Memory Disorders (Memory Loss) 08/2016 - 07/2015
3	Hypothermia 04/2016 - 01/2002
2	Food Addiction 01/2022 - 01/2020
2	Feeding and Eating Disorders (Eating Disorder) 01/2022 - 01/2020
2	Gliosis 01/2020 - 01/2015
2	Schizophrenia (Dementia Praecox) 01/2020 - 11/2011
2	Stroke (Strokes) 01/2018 - 03/2014
2	Inflammation (Inflammations) 01/2018 - 02/2014
2	Anti-N-Methyl-D-Aspartate Receptor Encephalitis 11/2017 - 01/2016
2	Arthralgia (Joint Pain) 01/2017 - 01/2013
2	AIDS-Related Complex (ARC) 01/2013 - 06/2011

Drug/Important Bio-Agent (IBA)

21	CannabinoidsIBA 01/2021 - 06/2005
19	Opioid Analgesics (Opioids)IBA 08/2021 - 02/2003
14	EndocannabinoidsIBA 01/2021 - 04/2006
14	Cannabinoid Receptors (Cannabinoid Receptor)IBA 11/2018 - 10/2005
12	Dronabinol (THC)FDA LinkGeneric 01/2021 - 01/2002
11	Analgesics (Analgesic Drugs)IBA 03/2022 - 11/2008
10	Pharmaceutical PreparationsIBA 03/2022 - 06/2011
10	Opioid Receptors (Opioid Receptor)IBA 01/2020 - 02/2004
10	Nicotine FDA Link 01/2017 - 01/2002
7	OrexinsIBA 05/2022 - 02/2012
7	delta Opioid Receptors (delta Opioid Receptor)IBA 01/2021 - 02/2003
6	Cocaine (Cocaine HCl)IBA 01/2022 - 10/2009
6	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 01/2021 - 01/2006
6	Morphine (MS Contin)FDA LinkGeneric 10/2019 - 04/2002
5	CB2 Cannabinoid ReceptorIBA 01/2021 - 01/2013
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2015
4	kappa Opioid Receptors (kappa Opioid Receptor)IBA 01/2021 - 02/2003
4	mu Opioid Receptors (mu Opioid Receptor)IBA 01/2019 - 02/2003
4	Iodoacetic AcidIBA 01/2019 - 01/2013
4	Anti-Anxiety Agents (Anxiolytics)IBA 04/2016 - 05/2013
4	Neurotransmitter Agents (Neurotransmitter)IBA 02/2016 - 10/2009
3	Amyloid (Amyloid Fibrils)IBA 01/2022 - 05/2015
3	Neprilysin (Neutral Endopeptidase)IBA 08/2021 - 01/2009
3	EnkephalinsIBA 08/2021 - 01/2009
3	1,1-dimethylbutyl-1-deoxy-Delta(9)-THCIBA 01/2020 - 01/2013
3	Messenger RNA (mRNA)IBA 01/2020 - 01/2006
3	Sigma-1 ReceptorIBA 10/2019 - 07/2013
3	LigandsIBA 09/2015 - 06/2012
3	Proteins (Proteins, Gene)FDA Link 08/2013 - 04/2007
3	Naloxone (Narcan)FDA LinkGeneric 11/2010 - 02/2004
2	mRNA VaccinesIBA 04/2022 - 11/2021
2	salicylhydroxamic acid (SHAM)IBA 03/2022 - 06/2010
2	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2022
2	Aromatic Amino Acids (Aromatic Amino Acid)IBA 12/2021 - 10/2020
2	Fragile X Mental Retardation ProteinIBA 01/2021 - 05/2013
2	4- (alpha- (4- allyl- 2,5- dimethyl- 1- piperazinyl)- 3- methoxybenzyl)- N,N- diethylbenzamideIBA 01/2021 - 06/2011
2	Therapeutic UsesIBA 01/2021 - 02/2006
2	Serotonin (5 Hydroxytryptamine)IBA 01/2021 - 07/2015
2	Peptides (Polypeptides)IBA 01/2021 - 05/2015
2	4- (2- ((5- methyl- 1- (2- naphthalenyl)- 1H- pyrazol- 3- yl)oxy)ethyl)morpholineIBA 10/2019 - 01/2019
2	Monoacylglycerol LipasesIBA 10/2019 - 10/2016
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2018 - 03/2014
2	oleoylethanolamideIBA 01/2018 - 03/2014
2	preproenkephalinIBA 01/2017 - 02/2005
2	glyceryl 2-arachidonate (2-arachidonoylglycerol)IBA 10/2016 - 08/2013
2	RimonabantIBA 08/2016 - 03/2010
2	Orexin ReceptorsIBA 04/2016 - 06/2012
2	Cannabinoid Receptor AgonistsIBA 02/2016 - 08/2009
2	AntibodiesIBA 01/2016 - 08/2013
2	Narcotic Antagonists (Opioid Antagonists)IBA 01/2016 - 04/2010
2	EnzymesIBA 05/2015 - 09/2013
2	Gabapentin (Neurontin)FDA LinkGeneric 03/2015 - 01/2006
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2015 - 02/2004
2	Calcium Channels (Calcium Channel)IBA 08/2013 - 04/2010
2	Phosphotransferases (Kinase)IBA 01/2013 - 10/2009

Therapy/Procedure

6	Analgesia 01/2021 - 02/2004
4	Ligation 01/2021 - 10/2009
4	Therapeutics 01/2021 - 09/2015
3	Self Administration (Administration, Self) 03/2022 - 06/2012
3	Behavior Control 01/2022 - 11/2018
2	Operative Surgical Procedures 03/2022 - 09/2020
2	Vagus Nerve Stimulation 01/2022 - 03/2020
2	Intra-Articular Injections 01/2017 - 01/2013